Details of the Drug-Related molecule(s) Interaction Atlas

General Information of Drug (ID: DM84LXE)

Drug Name
BGB-10188 Drug Info
Indication
Disease Entry ICD 11 Status REF
B-cell lymphoma 2A86 Phase 1 [1]
Solid tumour/cancer 2A00-2F9Z Phase 1 [1]
Cross-matching ID
TTD Drug ID
DM84LXE

Molecule-Related Drug Atlas

Molecule-Related Drug Atlas
Molecule Type:
DTT
Drug Status:
Approved Drug(s)
Clinical Trial Drug(s)
Download the Complete Related Drug List
Drug(s) Targeting PI3-kinase delta (PIK3CD)
Drug Name Drug ID Indication ICD 11 Highest Status REF
BAY 80-6946 DMLOS5R Follicular lymphoma 2A80 Approved [2]
Idelalisib DM602WT Chronic lymphocytic leukaemia 2A82.0 Approved [3]
Umbralisib DMYRBO1 Follicular lymphoma 2A80 Approved [4]
IPI-145 DMWA24P Follicular lymphoma 2A80 Approved [5]
Leniolisib DMWAD93 Stomach cancer 2B72 Approved [6]
Buparlisib DM1WEHC Breast cancer 2C60-2C65 Phase 3 [7]
INCB50465 DMZJP2T Diffuse large B-cell lymphoma 2A81 Phase 2 [8]
ME-401 DMK0UOY Follicular lymphoma 2A80 Phase 2 [8]
RP6530 DMYILGK Chronic lymphocytic leukaemia 2A82.0 Phase 2 [8]
Parsaclisib DMYBIFS Follicular lymphoma 2A80 Phase 2 [9]
⏷ Show the Full List of 10 Drug(s)

Molecular Interaction Atlas of This Drug

Molecular Interaction Atlas
Download the Complete Interaction Atlas for Visualization in Cytoscape

Drug Therapeutic Target (DTT)
DTT Name DTT ID UniProt ID MOA REF
PI3-kinase delta (PIK3CD) TTGBPJE PK3CD_HUMAN Inhibitor [1]

References

1 ClinicalTrials.gov (NCT04282018) Brief Title: Study of BGB-10188 as Monotherapy, and in Combination With Zanubrutinib, and Tislelizumab. U.S. National Institutes of Health.
2 2017 FDA drug approvals.Nat Rev Drug Discov. 2018 Feb;17(2):81-85.
3 2014 FDA drug approvals. Nat Rev Drug Discov. 2015 Feb;14(2):77-81.
4 Drugs@FDA. U.S. Food and Drug Administration. U.S. Department of Health Human Services. 2021
5 PI3K-delta and PI3K-gamma inhibition by IPI-145 abrogates immune responses and suppresses activity in autoimmune and inflammatory disease models. Chem Biol. 2013 Nov 21;20(11):1364-74.
6 Effective "activated PI3K syndrome"-targeted therapy with the PI3K inhibitor leniolisib. Blood. 2017 Nov 23;130(21):2307-2316.
7 Targeting the phosphoinositide 3-kinase pathway in cancer. Nat Rev Drug Discov. 2009 Aug;8(8):627-44.
8 Clinical pipeline report, company report or official report of the Pharmaceutical Research and Manufacturers of America (PhRMA)
9 Parsaclisib, a potent and highly selective PI3K inhibitor, in patients with relapsed or refractory B-cell malignancies. Blood. 2019 Apr 18;133(16):1742-1752.